Haemonetics CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
Haemonetics Corporation announced its 2026 Annual Meeting of Shareholders will be held on July 24, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.
NYSE
Haemonetics Corporation has filed definitive additional proxy materials with the SEC, indicating further disclosures related to its upcoming shareholder meeting.
NYSE
Haemonetics Corporation announces its 2025 Annual Meeting of Shareholders to be held on July 24, 2025, with proposals including the election of directors, executive compensation, and ratification of the accounting firm.
NYSE
Haemonetics Corporation has filed a definitive proxy statement with the SEC.
NYSE
Haemonetics Corporation has released its proxy statement outlining the agenda for its 2024 Annual Meeting of Shareholders, including the election of directors, executive compensation, and ratification of the independent auditor.